N-(1-piperidinyl)pivalamide | 925126-09-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(1-piperidinyl)pivalamide
• 英文别名: 2,2-dimethyl-N-piperidin-1-ylpropanamide
• CAS: 925126-09-6
• 化学式: C₁₀H₂₀N₂O
• mdl: MFCD08714894
• 分子量: 184.282
• InChiKey: MXKFNOGBOZWVFZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  NiCl2*2 acetonitrile 、 N-(1-piperidinyl)pivalamide 在 potassium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 19.0h， 以13%的产率得到
  参考文献：
  名称：

  Exceptional thermal stability and high volatility in mid to late first row transition metal complexes containing carbohydrazide ligands

  摘要：

  Treatment of metal(II) halides (metal = Cu, Ni, Co, Fe, Mn, Cr) with the potassium salts of carbohydrazides L-1-L-6 afforded Cu(L-1)(2) (75%), Cu(L-2)(2) (51%), Cu(L-3)(2) (23%), Co(L-1)(2) (57%), Cr(L-1)(2) (62%), Ni(L-1)(2) (76%), Ni(L-2)(2) (62%), Ni(L-3)(2) (62%), Ni(L-4)(2) (13%), Ni(L-5)(2) (11%), Ni(L-6)(2) (29%), [Fe(L-1)(2)](2) (28%), and [Mn(L-1)(2)](2) (12%) as crystalline solids, where L-1 = Me2NN=C(tBu)O-, L-2 = Me2NN=C(iPr)O-, L-3 = Me2NN=C(Me)O-, L-4 = (CH2)(5)NN=C(tBu)O-, L-5 = (CH2)(5)NN=C(iPr)O-, and L-6 = (CH2)(5)NN=C(Me)O-. These complexes were characterized by spectral and analytical techniques, and by X-ray crystal structure determinations for Cu(L-1)(2), Co(L-1)(2), Cr(L-1)(2), Ni(L-1)(2), and Fe(L-1)(2)](2). Cu(L-1)(2), Co(L-1)(2), Cr(L-1)(2), and Ni(L-1)(2) exist as square planar, monomeric complexes, whereas [Fe(L1)2]2 is a dimer. A combination of sublimation studies, thermal decomposition temperature determinations, and thermogravimetric/differential thermal analysis demonstrate that the Cu, Co, and Ni complexes Cu(L-1)(2), Cu(L-2)(2), Co(L-1)(2), Ni(L-1)(2), and Ni(L-2)(2) have the lowest sublimation temperatures and highest decomposition temperatures among the series. Additionally, these compounds have higher volatilities and thermal stabilities than commonly used ALD and CVD precursors. Hence, these new complexes have excellent properties for application as ALD precursors to Cu, Co, and Ni metal films. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2012.07.034
• 作为产物：
  描述：

  1-氨基哌啶 、 三甲基乙酰氯 在 三乙胺 作用下， 以 乙醚 为溶剂， 反应 17.0h， 以51.3%的产率得到N-(1-piperidinyl)pivalamide
  参考文献：
  名称：

  Exceptional thermal stability and high volatility in mid to late first row transition metal complexes containing carbohydrazide ligands

  摘要：

  Treatment of metal(II) halides (metal = Cu, Ni, Co, Fe, Mn, Cr) with the potassium salts of carbohydrazides L-1-L-6 afforded Cu(L-1)(2) (75%), Cu(L-2)(2) (51%), Cu(L-3)(2) (23%), Co(L-1)(2) (57%), Cr(L-1)(2) (62%), Ni(L-1)(2) (76%), Ni(L-2)(2) (62%), Ni(L-3)(2) (62%), Ni(L-4)(2) (13%), Ni(L-5)(2) (11%), Ni(L-6)(2) (29%), [Fe(L-1)(2)](2) (28%), and [Mn(L-1)(2)](2) (12%) as crystalline solids, where L-1 = Me2NN=C(tBu)O-, L-2 = Me2NN=C(iPr)O-, L-3 = Me2NN=C(Me)O-, L-4 = (CH2)(5)NN=C(tBu)O-, L-5 = (CH2)(5)NN=C(iPr)O-, and L-6 = (CH2)(5)NN=C(Me)O-. These complexes were characterized by spectral and analytical techniques, and by X-ray crystal structure determinations for Cu(L-1)(2), Co(L-1)(2), Cr(L-1)(2), Ni(L-1)(2), and Fe(L-1)(2)](2). Cu(L-1)(2), Co(L-1)(2), Cr(L-1)(2), and Ni(L-1)(2) exist as square planar, monomeric complexes, whereas [Fe(L1)2]2 is a dimer. A combination of sublimation studies, thermal decomposition temperature determinations, and thermogravimetric/differential thermal analysis demonstrate that the Cu, Co, and Ni complexes Cu(L-1)(2), Cu(L-2)(2), Co(L-1)(2), Ni(L-1)(2), and Ni(L-2)(2) have the lowest sublimation temperatures and highest decomposition temperatures among the series. Additionally, these compounds have higher volatilities and thermal stabilities than commonly used ALD and CVD precursors. Hence, these new complexes have excellent properties for application as ALD precursors to Cu, Co, and Ni metal films. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2012.07.034

文献信息

• [EN] METHODS FOR SYNTHESIZING 2-SUBSTITUTED IMIDAZOLES<br/>[FR] METHODES DE SYNTHESE D'IMIDAZOLES 2-SUBSTITUES
  申请人：SEPRACOR INC.

  公开号：WO1998046571A1

  公开（公告）日：1998-10-22

  (EN) The present invention is a method of preparing 2-substituted imidazoles from readily available imidazoles having a leaving group in the 2-position, by alkylating the imidazole under mild conditions to afford a 3-$i(N)-alkylated imidazolium salt; and coupling the imidazolium salt with a nucleophile also under mild conditions to afford a 2-substituted 3-$i(N)-alkylated imidazolium salt. The reaction product can optionally be isolated and purified. The 2-substituted 3-$i(N)-alkylated imidazolium salt is hydrolyzed to afford a 2-substituted imidazole. Alternatively, the imidazole is coupled with a nucleophile in the presence of fluoride ion to provide a 2-substituted imidazole.(FR) La présente invention concerne une méthode de préparation d'imidazoles 2-substitués à partir d'imidazoles facilement disponibles possédant un groupe partant situé dans la position 2, par alkylation de l'imidazole dans des conditions modérées pour obtenir un sel d'imidazolium 3-$i(N)-alcoylé; puis par couplage du sel d'imidazolium avec un nucléophile également dans des conditions modérées pour obtenir un sel d'imidazolium 2-substitué 3-$i(N)-alcoylé. Le produit de réaction peut éventuellement être isolé ou purifié. Le sel d'imidazolium 2-substitué 3-$i(N)-alcoylé est hydrolysé pour produire un imidazole 2-substitué. Dans un autre mode de réalisation, l'imidazole est couplé à un nucléophile en présence d'un ion de fluorure pour produire un imidazole 2-substitué.

  该发明涉及一种制备2-取代咪唑的方法，该方法利用在2位具有离去基团的易得到的咪唑，通过在温和条件下烷基化咪唑以得到3-$i(N)-烷基化咪唑盐，然后在同样温和的条件下将咪唑盐与亲核试剂偶联，以得到2-取代的3-$i(N)-烷基化咪唑盐。反应产物可以选择性地被分离和纯化。2-取代的3-$i(N)-烷基化咪唑盐被水解以得到2-取代咪唑。或者，在氟化物离子存在下，咪唑与亲核试剂偶联以提供2-取代咪唑。
• HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
  申请人：Miyaji Katsuaki

  公开号：US20090253751A1

  公开（公告）日：2009-10-08

  Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R 1 , R 2 , R 3 , L 1 , L 2 , X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

  提供了一种用于预防、治疗或改善激活血小板生成素受体有效对抗的疾病的化合物。该化合物由式(I)所表示（其中R1、R2、R3、L1、L2、X和Y在描述中被定义），该化合物的互变异构体、前药或药物可接受的盐或其溶剂化物。
• METHODS FOR SYNTHESIZING 2-SUBSTITUTED IMIDAZOLES
  申请人：SEPRACOR, INC.

  公开号：EP0977740A1

  公开（公告）日：2000-02-09
• EP0977740A4
  申请人：——

  公开号：EP0977740A4

  公开（公告）日：2001-01-17
• US8026368B2
  申请人：——

  公开号：US8026368B2

  公开（公告）日：2011-09-27